Curcumin C3 complex(Curcumin C3 complex) - 药物靶点：NF-κB x bFGF x mTOR_在研适应症：宫颈上皮内瘤样病变，人瘤病毒相关性宫颈癌，皮肤鳞状细胞癌_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Curcumin C3 ®、Curcumin/Demethoxycurcumin/Bisdemethoxycurcumin

靶点

NF-κB x bFGF x mTOR

作用方式

抑制剂

作用机制

NF-κB抑制剂(核因子NF-κB复合体抑制剂)、bFGF抑制剂(成纤维细胞生长因子2抑制剂)、mTOR抑制剂(丝氨酸/苏氨酸蛋白激酶mTOR抑制剂)

治疗领域

肿瘤泌尿生殖系统疾病

在研适应症

宫颈上皮内瘤样病变人瘤病毒相关性宫颈癌皮肤鳞状细胞癌

非在研适应症

寻常性银屑病放射性皮炎

原研机构

Lsu Health Shreveport

在研机构

Emory University

Lsu Health Shreveport

非在研机构

University of Rochester

University of Pennsylvania

权益机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

5

项与 Curcumin C3 complex 相关的临床试验

NCT04266275

/ Not yet recruiting临床2期IIT

An Investigation in the Use of Curcumin Topical Herbal Agent for the Treatment of Cervical Intraepithelial Neoplasia

The purpose of this study is to see if curcumin can suppress HPV infection in women with low-grade squamous intraepithelial lesions (LSIL) disease or treated high-grade squamous intraepithelial lesions (HSIL) disease. This study plans to explore the effect of curcumin as a potential medical treatment in HIV-uninfected and infected women with mild precancerous lesions of the cervix or recently treated high-grade precancerous lesions at risk for persistent HPV infection. About 200 women with low-grade precancerous lesions of the cervix or recently treated high-grade precancerous lesions will be enrolled to either insert 2000 mg of curcumin capsules in their vagina once a week or placebo after undergoing colposcopy or loop electrosurgical excision procedure (LEEP). They will have a repeat visit in 6 months where they will undergo a Pap smear and HPV test to determine if there are higher rates of HPV clearance after curcumin administration. If HPV is present or the Pap smear is abnormal, patients will then undergo colposcopic examination to evaluate cervical histology.

开始日期2027-04-01

申办/合作机构

Emory University

NCT03598309

/ Active, not recruiting临床2期IIT

Phase II Trial of Investigational Agents to Modulate Intermediate Endpoint Biomarkers, Including Pulmonary Nodules, in Former and Current Smokers

The purpose of this study is to find out if an investigational combination drug called Lovaza (made with fish oils)+Curcumin C3 Complex (made from a root called curcumin) can help reduce the size of lung nodules. Researchers also want to find out if the combination of Lovaza+Curcumin C3 Complex is safe and tolerable.

开始日期2019-06-05

申办/合作机构

H. Lee Moffitt Cancer Center & Research Institute, Inc.

NCT01490996

/ Completed临床1/2期IIT

A Phase I/IIa Study Combining Curcumin (Curcumin C3-Complex, Sabinsa) With Standard Care FOLFOX Chemotherapy in Patients With Inoperable Colorectal Cancer.

Oral curcumin (complex C3, Sabinsa Corp, Utah) will be given to patients with inoperable colorectal metastases who will be commencing standard care oxaliplatin-based (FOLFOX) chemotherapy for up to 12 cycles(approximately 6 months) of treatment.
Primary measurements focus on safety and tolerability. These will be recorded in real-time and report the number and severity of adverse events.
Secondary measurements will include efficacy, (measured by response rate with RECIST and overall survival in months) supported by biomarker analysis.

开始日期2012-02-01

申办/合作机构

University of Leicester

100 项与 Curcumin C3 complex 相关的临床结果

登录后查看更多信息

100 项与 Curcumin C3 complex 相关的转化医学

登录后查看更多信息

100 项与 Curcumin C3 complex 相关的专利（医药）

登录后查看更多信息

14

项与 Curcumin C3 complex 相关的文献（医药）

2023-10-31·Journal of toxicology

Assessment of Safety Profile of Activated Curcumin C3 Complex (AC3®), Enriched Extract of Bisdemethoxycurcumin from the Rhizomes of Curcuma longa

Article

作者: Pandey, Anjali ; Majeed, Muhammed ; Ibrahim A., Muhamad ; Thazhathidath, Smitha ; Bani, Sarang

The present work was carried out to investigate the toxic effects of Activated Curcumin C3 Complex (AC3®) through the methods of acute, subacute, subchronic, reproductive/developmental toxicity, and genotoxicity when administered orally in experimental rodents. The studies were carried out in line with OECD principles of good laboratory practice. A single-dose acute oral toxicity study was conducted on female Wistar rats that produced no toxic effects after 14 days (the observation period) of treatment. Subacute, subchronic, and reproductive/developmental studies were conducted in Wistar rats, divided equally into vehicle control, 125, 250, and 500 mg/kg dose groups along with recovery groups for vehicle control and high dose. In all the studies, there were no abnormal clinical signs/behavioral changes, reproductive and developmental parameters, or gross and histopathological changes. Likewise, no alteration was found in the body weight, hematology, and other biochemical parameters. Also, it did not show mutagenicity in the in vitro AMES test or clastogenicity and aneugenicity in the in vivo micronucleus test, indicating that AC3® did not induce any genotoxic effects. This revealed that oral administration of AC3® is safe in rodents, nonmutagenic, and had no observed adverse effects under experimental conditions.

2023-04-01·The Journal of frailty & aging

Effects of Curcumin C3 Complex® on Physical Function in Moderately Functioning Older Adults with Low-Grade Inflammation — A Pilot Trial

Article

作者: F.-C. Hsu ; P. Qiu ; K.T. Sibille ; C. Leeuwenburgh ; Robert T. Mankowski ; B. Sandesara ; Y. Lin ; S.D. Anton

BACKGROUND:

Natural dietary compounds that can modulate the inflammation process have the potential to improve physical function through a number of biological pathways, and thus may represent an alternative approach to avert functional decline compared to more time-burdening lifestyle interventions. In this pilot trial, we tested the feasibility and explored the effect of a nutritional compound, Curcumin C3 Complex® for improving physical function and muscle strength in moderately functioning older adults with low-grade inflammation.

METHODS:

Moderately functioning (short physical performance battery, SPPB <10) and sedentary older adults (>65 years) with low-grade systemic inflammation (c-reactive protein >1mg/dL) were randomized to receive Curcumin C3 Complex® (n=9) (1000mg/day) or placebo (n=8) groups for 12 weeks. All participants (age range: 66-94 years, 8 females and 9 males) underwent functional testing (SPPB and walking speed by the 400-meter walk test) and lower-limb strength (knee flexion and extension peak torque by the Biodex test) at baseline and 12 weeks. Venous blood was collected at baseline, 4, 8 and 12 weeks for safety blood chemistry analyses and biomarkers of inflammation.

RESULTS:

A total of 17 participants were randomized and completed the study. Adherence was high (> 90%) and there were no adverse events reported or abnormal blood chemistries reported. Based on effect sizes, participants in the Curcumin C3 Complex® group demonstrated large effect sizes in the SPPB (Cohen's effect size d=0.75) and measures of knee extension (d=0.69) and flexion peak torque (d=0.82). Effect sizes for galectin-3 (d=-0.31) (larger decrease) and interleukin-6 (d=0.38) (smaller increase) were small in the Curcumin C3 Complex® group compared to placebo.

CONCLUSION:

This pilot trial suggests that there were no difficulties with recruitment, adherence and safety specific to the study protocol. Preliminary findings warrant a Phase IIb clinical trial to test the effect of Curcumin C3 Complex® on physical function and muscle strength in older adults at risk for mobility disability.

2020-11-10·Current pharmaceutical design4区 · 医学

Synergistic Antioxidant and Antibacterial Activity of Curcumin-C3 Encapsulated Chitosan Nanoparticles

4区 · 医学

Article

作者: Huang, Fu-Yung ; Reddy, Desu N.K. ; Kumar, Ramya ; Wang, Shao-Pin

Background::

Recent studies have focused on the nanoformulations of curcumin to enhance its solubility and bioavailability. The medicinal properties of curcumin-C3 complex, which is a combination of three curcuminoids (curcumin, demethoxycurcumin and bisdemethoxycurcumin) is less explored.

Objective::

The aim of this study was to prepare curcumin-C3 encapsulated in chitosan nanoparticles, characterize and evaluate their antioxidant and antibacterial potential.

Methods::

Ionic gelation method was used to prepare curcumin-C3 nanoparticles and was characterized by Fourier transform infrared spectroscopy, X-ray diffraction, transmission electron microscopy and nanoparticle tracking analysis. In vitro assays were performed to assess drug release, antioxidant and antibacterial activities.

Results::

Curcumin-C3-chitosan nanoparticle showed an increased entrapment efficiency of >90%, drug release and improved antioxidant potential. Moreover, curcumin-C3-chitosan nanoparticle showed stronger inhibition of Escherichia coli and Staphylococcus aureus.

Conclusion::

Chitosan is a suitable carrier for curcumin-C3 nanoparticle and can be used as a drug delivery system in the treatment of inflammatory and bacterial diseases.

100 项与 Curcumin C3 complex 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
宫颈上皮内瘤样病变	临床2期	美国	Emory University	2027-04-01
人瘤病毒相关性宫颈癌	临床2期	美国	Emory University	2027-04-01
放射性皮炎	临床2期	美国	University of Rochester	2008-01-01
寻常性银屑病	临床2期	美国	University of Pennsylvania	2005-10-01
皮肤鳞状细胞癌	临床前	美国	Lsu Health Shreveport	2015-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01042938 (CTgov)	临床2期	放射性皮炎	35	Curcumin C3 Complex (Curcumin C3 Complex)	鑰範鬱願鏇鹹膚獵夢襯(齋餘餘襯構餘鬱積艱築) = 窪憲選製範餘鏇膚顧構憲範製壓醖鬱糧淵壓糧 (製鏇築蓋憲鹽簾衊願衊, 0.994) 更多	-	2012-06-20
				Placebo (Placebo)	鑰範鬱願鏇鹹膚獵夢襯(齋餘餘襯構餘鬱積艱築) = 糧餘願襯鏇鏇觸餘觸鏇憲範製壓醖鬱糧淵壓糧 (製鏇築蓋憲鹽簾衊願衊, 0.554) 更多